



We are contacting you regarding the sale of the assets of Tarveda Therapeutics, Inc. (the “Company”)

*TVA (ABC), LLC is the Assignee for the Benefit of Creditors (the “Assignee”) of Tarveda Therapeutics, Inc. pursuant to a General Assignment that was dated April 4, 2022, in connection with which a proceeding was filed in the Delaware Chancery Court pursuant to 10 Del. C. § 7381 on April 7, 2022. Pursuant to the Assignment, the Assignee is vested in all the assets formerly owned by the Company, subject to all liens, claims and encumbrances thereon in existence as of the date of the Assignment.*

*As part of the Assignee’s duties in administering the Company’s assignment estate (the “Assignment Estate”), the Assignee is responsible for implementing a commercially reasonable sale process in connection with the sale (the “Sale”) of substantially all the Assignment Estate’s assets (the “Assets”).*

Tarveda Therapeutics, Inc., is a pharmaceutical development company focused on precision oncology medicines.

Please note, this will be an expedited sale process. Rock Creek Advisors, acting on behalf of the Assignee, is seeking an interested party to purchase all the Company’s assets.

Upon receipt of an executed confidentiality agreement in form and substance similar to the attached, and upon further receipt of an Indication of Interest demonstrating that you have a bona fide interest in providing a proposal to the Assignee to purchase all the Company’s assets, Rock Creek will provide access information for Tarveda Therapeutics’ Confidential electronic data room.

Rock Creek will provide any interested party such due diligence access or information as Rock Creek and the Assignee determine to be reasonably requested and appropriate under the circumstances.

Rock Creek and the Tarveda Therapeutics management team are available to discuss this opportunity at your convenience.

If there is another person at your firm who would be more appropriate to review this matter, please let us know and/or forward this information accordingly. Also, if your firm is not interested in pursuing this opportunity, your response and indication is much appreciated in order that we do not follow up further.